PL-6983 for Female Sexual Dysfunction

PL-6983 is the lead compound in a new series of melanocortin receptor-specific peptides developed by Palatin Technologies.  PL-6983 has demonstrated efficacy in inducing erections in animal models and in inducing sexual behavior in an animal model of female sexual dysfunction (FSD). In animal models at doses effective for a sexual response, PL-6983 resulted in significantly smaller increases in blood pressure compared to bremelanotide.

Palatin Technologies is developing PL-6983 primarily for FSD, a major unmet medical need.  Depending on results of clinical trials, Palatin Technologies may also seek to develop PL-6983 for erectile dysfunction (ED).

For more information on PL-6983 for Female Sexual Dysfunction, download the fact sheet.